Repeated Binge Exposures to Amphetamine and Methamphetamine: Behavioral and Neurochemical Characterization1

  1. David S. Segal and
  2. Ronald Kuczenski
  1. Department of Psychiatry, School of Medicine, University of California of San Diego at La Jolla, California

    Abstract

    Stimulant psychosis and addiction are most commonly associated with repeated, high-dose binges or runs, typically preceded by a more intermittent pattern of stimulant abuse. We previously reported that rats exposed to an escalating dose-run pattern of amphetamine administration exhibited changes in their behavioral response profile that differed both qualitatively and quantitatively from the response to either acute or intermittent daily treatment. To determine the generality of these effects and characterize further the nature of the behavioral and neurochemical changes of this treatment, rats received single daily injections of amphetamine (2.5 or 4.0 mg/kg s.c.) or equimolar doses of methamphetamine, followed by multiple runs (four daily injections at 2-hr intervals) with the pretreatment dose. This treatment resulted in a unique behavioral profile, including a profound increase in the relative expression of locomotion vs.stereotypy. The markedly enhanced poststereotypy locomotor activation was characterized by repeated “burst”-like episodes of ambulation. The number of runs required for the emergence of this behavior was dose dependent and was similar for the two drugs except that with methamphetamine, there also was a marked prolongation of the poststereotypy locomotor response during run exposures. During runs, both drugs produced a decline in the caudate but not the nucleus accumbens microdialysate dopamine response, whereas only methamphetamine produced a decline in the serotonin response that was apparent in both regions. The possible relationship between these behavioral and neurochemical changes and their implications for high dose patterns of stimulant abuse are discussed.

    Footnotes

    • Send reprint requests to: Dr. David S. Segal, Psychiatry Department (0603), UCSD School of Medicine, La Jolla, CA 92093.

    • 1 This work was supported in part by United States Public Health Service Grants DA-01568 and DA-04157. D.S.S. is the recipient of United States Public Health Service NIMH Career Scientist Award MH-70183.

    • 2 D. S. Segal and R. Kuczenski, unpublished observations.

    • Abbreviations:
      AMPH
      amphetamine
      METH
      methamphetamine
      DA
      dopamine
      NE
      norepinephrine
      5-HT
      serotonin
      SDI
      single daily injection(s)
      ICI
      intercrossover interval
      ANOVA
      analysis of variance
      AUC
      area under the curve
      • Received November 20, 1996.
      • Accepted April 15, 1997.
    « Previous | Next Article »Table of Contents